We additionally found that established ccRCC cell lines also were less sensitive to 3BrPA treatment, despite the presence of SLC16A1 at almost the same elevated levels as in the primary ccRCC cells. This evidence concerns the gene SLC16A1 and nonpapillary renal cell carcinoma.